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During its long and rich history, medical sciences have
undergone several changes of paradigms. In this quest to
develop more potent drugs, less invasive surgical techni-
ques and more sophisticated diagnostic approaches
(among other goals) medicine has contributed decisively
to our well being and longevity. Some of these major
accomplishments, which altered the course of humanity
are: the development of antibiotics, organ transplantation
and radiography. Medicine has recently reached a new
hallmark: RNA interference (RNAi), a Nobel prize winning
technology which promises to promote medical care at the
molecular level, by regulating genes in our favor.
RNAi was first successfully used in C. elegans, a labora-
tory model species, by microinjecting dsRNAs in the
worm’s gonad. However, the works that laid the founda-
tions for the development of the technique were initially
done in plants and fungi. RNAi was accidentally discov-
ered, when white transgenic petunias were obtained
instead of deep purple ones [1]; a similar paradoxal result
was obtained when white transgenic colonies of Neuro-
spora sp were observed in place of orange ones [2]. These
findings revealed the existence of an unknown potent
mechanism of gene regulation, which could be tamed for
diverse uses, from basic science, agriculture, animal health
and medicine.
From these seminal observations, during a period of
nearly 10 years, researchers aimed at characterizing, at
the genetic and biochemical levels, the process of RNAi.
By the year 2001, scientists were ready to perform the
initial analyses in human cells [3]. Since then, RNAi has
been used as a tool in molecular biology, allowing potent
and specific gene silencing. This is achieved by the intro-
duction of double-stranded RNA molecules (dsRNAs),
which ultimately lead to the degradation of messenger
RNAs (mRNAs), i.e., gene silencing. The molecular
mechanism behind RNAi requires the activation of an
endogenous pathway which is present in almost all
eukaryotic cells. This pathway is responsible for detecting
long dsRNAs and, subsequently, promoting their cleavage
by an enzyme called dicer, into small duplexes of
approximately 21-25 bp called siRNAs (small interfering
RNAs). Alternatively, siRNAs can be directly introduced
into the cytoplasm of eukaryotic cells. This second
approach is required in mammalian cells, since dsRNAs
longer than 30 bp induce apoptosis. siRNAs are subse-
quently transferred to a complex called RISC (RNA-
induced silencing complex), where one strand of the
duplex is destroyed and the other remains intact (desig-
nated guide strand). RISC then searches the cytoplasm
for mRNA molecules with sequence complementarity to
the guide strand. Once a mRNA with full complementar-
ity is found, slicer (an endoribonuclease which is part of
RISC) performs the cleavage of target mRNA [4].
Therefore, RNAi can be used as a technique that takes
advantage of an endogenous biochemical pathway, direct-
ing it to the destruction of specific target transcripts
(gene silencing). In addition, RNAi can be used to pro-
duce transgenic animals (known as knockdown animals),
resembling the null phenotype (- / -). Additionally, since
RNAi may be tamed to promote silencing efficiencies
ranging from 0.1% to 100% [5,6], animals with partial
phenotypes , known as hypomorfic, may generated.
These hypomorfic individuals are very informative since
they reveal intermediary and unprecedented phenotypes
and because the null genetic construction may happen to
be unviable [7].
Currently, most studies use RNAi as a tool for reverse
genetics (identification of gene function), but the applica-
tions are numerous: i) disease control (viruses [8]; bacterial
diseases [9]; parasites, [10]); genetic [11]; tumors [12], ii)
production of animals of commercial interest [13] and iii)
production of animal models for research use [14]. Other
possible future applications include: control of drug* Correspondence: icendes@unicamp.br2Department of Medical Genetics, Faculty of Medical Sciences, University of
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consumption [15], pain relief [16], modulation of sleep
[17], among many others.
Another relevant feature of RNAi is its temporary effect
- long lasting knockdown is only observed in C. elegans
and a few other species. Therefore, in order to study genes
with constitutive expression, it is necessary to combine
long-term strategies such as the production of transgenic
animals encoding shRNAs (similar to siRNAs) or the use
of viral vectors. On the other hand, this transitory charac-
teristic can also be used as an advantage, when one con-
siders RNAi as a therapetical strategy.
Furthermore, the control of gene expression via RNAi
can be modulated in time and directed to specific cells
or organs. The identification of viral proteins capable of
suppressing RNAi, such as p19 [18] allows for future
applications, as well as the use of inducible promoters
(high temperature, drugs).
All these new developments have recently led to the
first published human clinical trials with very promising
results [19].
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